Single-dose Universal Hepatitis A Immunization in One-year-old Children in Argentina: High Prevalence of Protective Antibodies up to 9 Years After Vaccination

Pediatr Infect Dis J. 2016 Dec;35(12):1339-1342. doi: 10.1097/INF.0000000000001322.

Abstract

Background: Single-dose hepatitis A virus (HAV) vaccination was implemented in all Argentinean children 12 months of age in 2005. Previous studies demonstrated high prevalence of protective antibody response 4 years after single-dose vaccination. This study assessed long-term seroprotection against HAV after vaccination.

Methods: Children who received 1 dose of HAV vaccine at 1 year of age at least 6 years before enrollment were included at 5 centers in Argentina between 2013 and 2014. Demographic and socioeconomic characteristics were collected through a questionnaire. Blood samples were tested for anti-HAV antibodies. Antibody values ≥10 mIU/mL were considered seroprotective. Logistic regression analysis was performed to evaluate the association between demographic and socioeconomic variables and seroprotection.

Results: A total of 1088 children were included, with a median postvaccination interval of 7.7 years (range 6.3-9.2 years). Of these children, 97.4% (95% confidence interval: 96.3%-98.3%) had protective antibodies against HAV. No association between demographic or socioeconomic variables and seroprotection was found. Geometric mean concentration of antibody levels against HAV was 170.5 mUI/mL (95% confidence interval: 163.2-178.2 mUI/mL).

Conclusions: Single-dose universal hepatitis A immunization in 1-year-old children resulted in sustained immunologic protection for up to 9 years in Argentina. These findings, along with the low current disease burden, confirm the success of the intervention.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Argentina
  • Child
  • Female
  • Follow-Up Studies
  • Hepatitis A / prevention & control*
  • Hepatitis A Antibodies / blood*
  • Hepatitis A Vaccines / administration & dosage
  • Hepatitis A Vaccines / immunology*
  • Hepatitis A virus / immunology*
  • Humans
  • Infant
  • Male
  • Prevalence

Substances

  • Hepatitis A Antibodies
  • Hepatitis A Vaccines